Bisphosphonate Treatment and Related Agents in Children - Osteogenesis Imperfecta - page 463

osteogenesis imperfecta treated with bisphosphonates. J Pediatr
Orthop 2005;25:332-5.

[88] Marini JC, Hopkins E, Glorieux FH, Chrousos GP, Reynolds JC,

Gundberg CM, et al. Positive linear growth and bone responses
to growth hormone treatment in children with types III and IV
osteogenesis imperfecta: high predictive value of the carboxy-
terminal propeptide of type I procollagen. J Bone Miner Res
2003;18:237-43.

[78] Rauch F, Munns C, Land C, Glorieux FH. Pamidronate in

children and adolescents with osteogenesis imperfecta:
effect of treatment discontinuation. J Clin Endocrinol Metab
2006;91:1268-74.

[79] Ward KA, Adams JE, Freemont TJ, Mughal MZ. Can bisphos-

phonate treatment be stopped in a growing child with skeletal
fragility? Osteoporos Int 2007;18:1137-40.

[89] Rauch F, Travers R, Paritt AM, Glorieux FH. Static and dynamic

bone histomorphometry in children with osteogenesis imper-
fecta. Bone 2000;26:581-9.

[80] Papapoulos SE, Cremers SC. Prolonged bisphosphonate release

after treatment in children. N Engl J Med 2007;356:1075-6.

[90] Delmas PD. Treatment of postmenopausal osteoporosis. Lancet

2002;359:2018-26.

[81] Munns CF, Rauch F, Ward L, Glorieux FH. Maternal and fetal

outcome after long-term pamidronate treatment before concep-
tion: a report of two cases. J Bone Miner Res 2004;19:1742-5.

[91] Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt

JA, et al. Skeletal changes in rats given daily subcutaneous
injections of recombinant human parathyroid hormone (1-34)
for 2 years and relevance to human safety. Toxicol Pathol
2002;30:312-21.

[82] Chan B, Zacharin M. Maternal and infant outcome after pami-

dronate treatment of polyostotic ibrous dysplasia and osteogen-
esis imperfecta before conception: a report of four cases. J Clin
Endocrinol Metab 2006;91:2017-20.

[92] Quemerais-Durieu MA, Kerlan V, Chabre O. Therapeutic inno-

vation in osteoporosis (antisclerostin antibody and denosumab).
Ann Endocrinol (Paris) 2011;72(Suppl 1):S15-22. [83] Djokanovic N, Klieger-Grossmann C, Koren G. Does treatment

with bisphosphonates endanger the human pregnancy? J Obstet
Gynaecol Can 2008;30:1146-8.

[93] Semler O, Netzer C, Hoyer-Kuhn H, Becker J, Eysel P,

Schoenau E. First use of the RANKL antibody denosumab in
osteogenesis imperfecta type VI. J Musculoskelet Neuronal
Interact 2012;12:183-8.

[84] Levy S, Fayez I, Taguchi N, Han JY, Aiello J, Matsui D, et al.

Pregnancy outcome following in utero exposure to bisphospho-
nates. Bone 2009;44:428-30. [94] Marini JC, Gerber NL. Osteogenesis imperfecta. Rehabilitation

and prospects for gene therapy. JAMA 1997;277:746-50. [85] Kruse HP, Kuhlencordt F. On an attempt to treat primary and

secondary osteoporosis with human growth hormone. Horm
Metab Res 1975;7:488-91.

[95] Millington-Ward S, McMahon HP, Farrar GJ. Emerging thera-

peutic approaches for osteogenesis imperfecta. Trends Mol Med
2005;11:299-305. [86] Antoniazzi F, Bertoldo F, Mottes M, Valli M, Sirpresi S,

Zamboni G, et al. Growth hormone treatment in osteogenesis
imperfecta with quantitative defect of type I collagen synthesis.
J Pediatr 1996;129:432-9.

[96] Chamberlain JR, Deyle DR, Schwarze U, Wang P, Hirata RK,

Li Y, et al. Gene targeting of mutant COL1A2 alleles in mesen-
chymal stem cells from individuals with osteogenesis imper-
fecta. Mol Ther 2008;16:187-93. [87] Vieira NE, Marini JC, Hopkins E, Abrams SA, Yergey AL.

Effect of growth hormone treatment on calcium kinetics in
patients with osteogenesis imperfecta type III and IV. Bone
1999;25:501-5.

[97] Forlino A, Cabral WA, Barnes AM, Marini JC. New perspectives

on osteogenesis imperfecta. Nat Rev Endocrinol 2011;7:540-57.